Robuvit French Oak Wood Lignum Extract
Also known as: Robuvit, French Oak Wood Extract, Quercus robur wood lignum extract
Overview
Robuvit is a standardized polyphenol-rich extract derived from the wood of the French oak tree (Quercus robur). It is specifically known for its unique ellagitannins, called roburins, which are metabolized by gut microbiota into bioactive urolithins. While oak wood polyphenols have historically been consumed through beverages aged in oak barrels, Robuvit offers a concentrated and consistent dose. Its primary applications include enhancing energy metabolism, reducing fatigue, and improving physical performance and recovery. Research on Robuvit encompasses over 20 clinical trials, involving more than 1100 subjects, with evidence stemming from randomized controlled trials (RCTs) and mechanistic studies. The overall quality of evidence is considered moderate, with several well-conducted RCTs supporting its benefits, though large-scale meta-analyses specifically on Robuvit are not yet available.
Benefits
Robuvit offers several evidence-based benefits, primarily centered on energy and recovery. It significantly increases subjective energy levels and reduces fatigue in healthy individuals and those with conditions like chronic fatigue syndrome, PTSD, and burnout, as shown in multiple RCTs. This effect is linked to its ability to enhance mitochondrial function; its active metabolites, urolithins, promote mitophagy (the removal and renewal of dysfunctional mitochondria), leading to improved cellular energy production. Clinical studies also indicate benefits in recovery from various conditions, including flu, mononucleosis, surgery, heart failure, and liver/kidney insufficiency. Furthermore, Robuvit stimulates protein synthesis and muscle growth, contributing to enhanced endurance and vigor. Its high antioxidant capacity significantly decreases plasma oxidative stress markers, providing cellular protection. Secondary effects, such as improvements in erectile function, mood stabilization, and reduction of inflammatory markers like C-reactive protein (CRP) by up to 64%, have been reported but require further confirmation. Significant increases in energy scores and decreases in fatigue symptoms have been observed after just 4 weeks of 300 mg/day supplementation. Benefits have been demonstrated across healthy adults, elderly individuals, and patients experiencing fatigue-related conditions.
How it works
Robuvit's mechanism of action is primarily driven by its ellagitannins (roburins), which are metabolized by gut microbiota into bioactive urolithins. These urolithins are crucial for inducing mitophagy, the selective degradation of damaged mitochondria, thereby promoting mitochondrial renewal and enhancing ATP production through improved NADH-dehydrogenase activity. Beyond mitochondrial support, the extract stimulates ribosomal protein translation, which facilitates protein synthesis and muscle growth. Its potent antioxidant properties further contribute by reducing oxidative stress and protecting cells from damage. The bioavailability and efficacy of Robuvit are influenced by an individual's gut microbiota composition, as this dictates the efficiency of urolithin production.
Side effects
Robuvit is generally considered well-tolerated, with no serious adverse effects reported in clinical trials at typical dosages of 300 mg/day. No significant side effects have been documented in studies. Currently, there are no established drug interactions or contraindications associated with Robuvit. However, safety data for specific populations, such as pregnant or lactating women and children, are limited, and extensive studies in these groups have not been conducted. While no adverse effects have been noted in clinical trials, individuals with pre-existing medical conditions or those taking other medications should consult a healthcare professional before starting supplementation. The long-term safety beyond 8 weeks of use has not been extensively studied, though short-term use appears safe.
Dosage
The minimum effective dose of Robuvit, as established in clinical trials, is 300 mg per day. This dosage is typically administered as 100 mg three times daily. This 300 mg/day regimen has proven effective for improving energy levels and reducing fatigue. While a maximum safe dose has not been clearly defined, clinical studies have not reported toxicity at the studied dosages. For optimal absorption, it is recommended to take divided doses (e.g., three times daily) with meals. Robuvit is commonly available in oral capsule form, standardized for its polyphenol content. It's important to note that the absorption and efficacy of Robuvit are influenced by individual gut microbiota, as they are responsible for converting roburins into bioactive urolithins. Therefore, diet and overall microbiome health may impact its effectiveness.
FAQs
Is Robuvit safe for long-term use?
Clinical studies have shown good safety for up to 8 weeks of use. Data on longer-term safety are currently limited, so consultation with a healthcare professional for extended use is advisable.
How soon can effects be expected?
Improvements in energy levels and reduction in fatigue symptoms have been observed within 4 weeks of consistent supplementation with Robuvit.
Does everyone produce urolithins?
No, the production of urolithins from Robuvit's ellagitannins depends on an individual's gut microbiota. Robuvit may help increase the number of individuals who are urolithin producers.
Can Robuvit replace other fatigue treatments?
Robuvit may serve as a complementary option for managing fatigue. However, it should not replace prescribed medical treatments without prior consultation with a healthcare professional.
Research Sources
- https://pmc.ncbi.nlm.nih.gov/articles/PMC8573807/ – This systematic review by Weichmann et al. (2021) analyzed over 20 clinical trials involving 1172 subjects, concluding that Robuvit increases urolithin levels, enhances mitophagy, reduces oxidative stress, and improves energy and fatigue across various populations. It highlights the heterogeneity of study designs and the absence of a large-scale meta-analysis as limitations.
- https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2020.00074/full – Ferianec et al. (2020) conducted a double-blind, placebo-controlled RCT (n=66) in post-hysterectomy patients, demonstrating that 8 weeks of 300 mg/day Robuvit increased serum urolithin concentrations. This study confirmed the bioavailability and metabolite formation of Robuvit, although its primary focus was on biochemical endpoints rather than clinical outcomes.
- https://pmc.ncbi.nlm.nih.gov/articles/PMC4690515/ – Kolesarova et al. (2015) performed an 8-week RCT with 40 healthy elderly subjects, showing that 300 mg/day Robuvit significantly improved subjective energy levels and reduced fatigue symptoms, as measured by validated questionnaires. The study reported no adverse effects, despite its small sample size, indicating a well-controlled design.
- https://www.liebertpub.com/doi/pdf/10.1089/jmf.2020.0165 – This source provides a comprehensive overview of Robuvit's clinical effects, supporting its role in increasing urolithin levels, enhancing mitophagy, reducing oxidative stress, and improving energy and fatigue. It serves as a foundational reference for the benefits and mechanisms of Robuvit.
- https://nutraceuticalbusinessreview.com/how-robuvit-can-help-with-mood-swings-restless-sleep-stress-and-fatigue--200929 – This article discusses potential secondary benefits of Robuvit, including improvements in mood stabilization and reduction of inflammatory markers like C-reactive protein (CRP). While these effects are reported, the article suggests they require further confirmation through more extensive research.
